Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: <scp>KEYNOTE</scp>‐013

Vincent Ribrag

Institut Gustave Roussy Villejuif France
David E. Avigan

Beth Israel Deaconess Medical Center Harvard Medical School Boston MA
Damian J. Green

University of Washington Fred Hutchinson Cancer Research Center Seattle WA
Trisha Wise‐Draper

University of Cincinnati Cancer Institute Cincinnati OH
Juan G. Posada

Central Texas Veterans Affairs Health Care System Temple TX
Ravi Vij

Center for Advanced Medicine Washington University School of Medicine St. Louis MO
Ying Zhu

Merck & Co., Inc. Kenilworth NJ
Mohammed Z. H. Farooqui

Merck & Co., Inc. Kenilworth NJ
Patricia Marinello

Merck & Co., Inc. Kenilworth NJ
David S. Siegel

Hackensack University Medical Center Hackensack NJ